key: cord-0938858-y5xzebwi
authors: Abdoli, Asghar; Aalizadeh, Reza; Aminianfar, Hossein; Kianmehr, Zahra; Teimoori, Ali; Azimi, Ebrahim; Emamipour, Nabbi; Eghtedardoost, Marzieh; Siavashi, Vahid; Jamshidi, Hamidreza; Hosseinpour, Mohammadreza; Taqavian, Mohammad; Jalili, Hasan
title: Safety and potency of BIV1‐CovIran inactivated vaccine candidate for SARS‐CoV‐2: A preclinical study
date: 2021-10-26
journal: Rev Med Virol
DOI: 10.1002/rmv.2305
sha: a98abddadcb5e1c02c0f6c8b94733150f1e01d90
doc_id: 938858
cord_uid: y5xzebwi

The development of effective and safe COVID‐19 vaccines is a major move forward in our global effort to control the SARS‐CoV‐2 pandemic. The aims of this study were (1) to develop an inactivated whole‐virus SARS‐CoV‐2 candidate vaccine named BIV1‐CovIran and (2) to determine the safety and potency of BIV1‐CovIran inactivated vaccine candidate against SARS‐CoV‐2. Infectious virus was isolated from nasopharyngeal swab specimen and propagated in Vero cells with clear cytopathic effects in a biosafety level‐3 facility using the World Health Organization’s laboratory biosafety guidance related to COVID‐19. After characterisation of viral seed stocks, the virus working seed was scaled‐up in Vero cells. After chemical inactivation and purification, it was formulated with alum adjuvant. Finally, different animal species were used to determine the toxicity and immunogenicity of the vaccine candidate. The study showed the safety profile in studied animals including guinea pig, rabbit, mice and monkeys. Immunisation at two different doses (3 or 5 μg per dose) elicited a high level of SARS‐CoV‐2 specific and neutralising antibodies in mice, rabbits and nonhuman primates. Rhesus macaques were immunised with the two‐dose schedule of 5 or 3 μg of the BIV1‐CovIran vaccine and showed highly efficient protection against 10(4) TCID50 of SARS‐CoV‐2 intratracheal challenge compared with the control group. These results highlight the BIV1‐CovIran vaccine as a potential candidate to induce a strong and potent immune response that may be a promising and feasible vaccine to protect against SARS‐CoV‐2 infection.

The impact of vaccines on human health and control of infectious diseases is one of the brightest triumphs in the history of science. 1 Candidate platforms for coronavirus disease in 2019 (COVID- 19) vaccines are categorised into five major types: recombinant viral tick-borne encephalitis virus (TBEV) in vaccine development. 5 Initially, back in 1936, chemical inactivation was successfully applied to manufacture the influenza vaccine. 6 Experience with that vaccine led to a formalin-inactivated polio vaccine developed by Jonas Salk that came into use in 1955. 7 Provost and coworkers prepared a hepatitis A vaccine based on chemical inactivation with formalin in 1986. 8 The high efficacy of the hepatitis A vaccine testifies to the ability of careful inactivation to retain immunogenicity.

Vaccine development procedures depend on the selection of antigens, vaccine platforms, route of administration and regimen number.

Since the whole virus has all viral structural proteins, immune cells can recognise all viral immunogenic proteins present in its structure. An inactive SARS-CoV-2 vaccine similar to the native virus has four structural proteins, known as the S (spike), E (envelope), M (membrane) and N (nucleocapsid) proteins. 4 The S protein is the main target for neutralising antibodies in all coronaviruses, which is composed of S1 and S2 subunits. SARS-CoV-2 spike protein covers several distinct antigenic sites, comprising several receptor-binding domain (RBD) epitopes along with non-RBD epitopes. 9 Although antibodies against nucleoprotein (N), which is the most abundant protein in coronavirus, 10, 11 are unlikely to neutralise the virus, they confer protection against mouse hepatitis virus and coronavirus in mice. 12 The duration of the antibody response for SARS-CoV-2 has not been well defined. However, previous longitudinal studies of patients with SARS-CoV infection report that neutralising SARS-CoV antibodies last more than 3 years after the onset of symptoms. 13 Inactivated vaccines are formulated with potent adjuvant and need boosters to maintain satisfactory and long-term immunity. The most commonly used adjuvants in human vaccines are aluminium salts whose activity was defined in 1926. 14 Due to COVID-19 cytokine storm, 15, 16 alum, an adjuvant that promotes Th2-type immunity, may reduce immunopathology and seems to be a suitable option for vaccine formulation. 17 Inactivated SARS-CoV-2 vaccines may have better efficacy against variants that have mutations in the spike protein. In the present study, the efficiency and safety of an inactivated whole-virus SARS-CoV-2 candidate vaccine (BIV1-CovIran vaccine) were determined through preclinical studies.

All experiments with live SARS-CoV-2 viruses were performed in a biosafety level-3 facility according to World Health Organisation (WHO) guidelines. 18 The virus was isolated from a nasopharyngeal sample from a COVID-19 patient. Before infecting monolayer Vero cells (ATCC# CCL81), samples were diluted with a viral transfer medium containing antibiotics and passed through a 0.22 μm filter (Sartorius). Infected Vero cells were maintained in Dulbecco's modified Eagle's medium (Bio Idea) supplemented with 10% heatinactivated foetal bovine serum (FBS) and incubated for 72 h at 37°C in a 5% CO 2 incubator. Virus growth was verified through cytopathic effects (CPE), gene detection and electron microscopy.

The SARS-CoV-2 virus titre was determined by 50% tissue culture infective dose (TCID50). 19 Vero cells (1-2 � 10 4 cells/mL) were seeded in 96 well plates and incubated for 16-24 h at 37°C temperature. Serial 10-fold dilutions of virus-containing samples were added to the 96-well culture plate and cultured for 3-7 days in a 5% CO 2 incubator at 37°C, and cells were checked under a microscope for the presence of CPE. The virus titre was calculated by the Spearman Karber method. 20 After four passages, viral RNA was extracted from the clarified cell culture supernatant of infected Vero cells by RNA extraction kit (Rojetechnologies), and converted to cDNA. Whole-genome sequencing was carried out using the Sanger method. For evaluation of viral genome sequence the final passage (P10) was sequenced by Sanger sequencing. The sequences are classified as a B4 lineage by PANGO lineage finder. The list of mutations is shown in Supplementary Data 1 (Excel file). In the S region of SARS-CoV-2 three mutations were shown that include amino-acid change D416G, deletion isoleucine 210 and synonymous mutation in 294 (C > T). 3-UTR and 5-UTR of the genome were sequenced partially. The quality of the sequences in each mutated position were evaluated. Low quality reads were sequenced again. 

The inactivated virus solution was concentrated via ultrafiltration and buffer was exchanged using diafiltration. Purification of the inactivated virus was performed with two methods: ultracentrifugation and chromatography. In the first method, the concentrated inactivated virus solution was layered on the discontinuous sucrose gradient (20%/60% w/v) and centrifuged in an Optima XL-90 Beckman rotor Ti-90 (4°C, 3.5 h, 100,000 g). The purified viral particles were harvested from the boundary of the two sucrose layers (20%/ 60% w/v), and dialysed against phosphate buffer saline (PBS; Bio Idea) overnight at 4°C to eliminate the residual sucrose. 22, 23 In the second method, the ÄKTA ready chromatography system (GE Healthcare Life Sciences) together with the cellufine sulphate as an affinity chromatography was applied to purify the inactivated virus.

Dialysed and clarified inactivated virus solution was loaded on to the column to capture the viral particles. Subsequently, the column was washed with 10 column volume of load buffer (10 mM Na Phosphate, 150 mM NaCl pH 7.4) to through away faintly linked impurities. The inactivated SARS-CoV-2 captured on the column was then eluted via 10 mM phosphate buffer, 2.0 M sodium chloride, pH 7.4. 24, 25 The protein composition of the purified virus was confirmed through SDS-PAGE analysis followed by staining with silver nitrate and western blot. The total protein concentration was determined by the Bradford assay. The structural integrity of the isolated virus particles was monitored using the transmission electron microscope (TEM). Viral particles were absorbed on the carbon-coated grids and stained with 1% uranyl acetate. Grids were analysed using a transmission electron microscope (TEM, EM208S, Philips, 100 kV) at final magnifications of 90,000�.

Alhydrogel ® adjuvant 2% (Brenntag Biosector), referred to as alum, is an aluminium hydroxide wet gel suspension which used as vaccine adjuvant in the current study. The working concentration of Alhydrogel ® adjuvant 2% was 250 μg for vaccine used in monkeys and rabbits and it was 50 μg in mice. For vaccine formulation, the purified inactivated viral particles (antigen) were sterilised using filtration. A mixture of alum-antigen in two doses, a high dose of 5 µg and a low dose of 3 μg, of inactivated viral antigen was prepared and well mixed. 26 

The animals were used in this study were as follow: 6-8 weeks old rodents (BALB/c mice, Guinea pigs and Wistar Rat), lagomorph (3-6 months New Zealand White rabbits) and non-human primates ( 

The abnormal toxicity test To perform the abnormal toxicity test, five SW1 mice 6-to 8-weekold were injected intraperitoneally with 0.5 mL full human dose vaccine (1 FHD). Additionally, in two guinea pigs, FHD (0.5 mL) was injected intraperitoneally. The injected mice and guinea pigs were weighed daily for 7 days and observed for any evidence of ill-health.

At the end of the 7-day observation period the mice were sacrificed, and gross examination of organs and tissues were performed by trained veterinary pathologist. The vaccine passes if none of the animal die or show any sign of illness for 7 days. 27, 28 Single dose toxicity study and local tolerance study

The local tolerance was assessed as part of the single-dose toxicity by intramuscular administration of full human dose to 6-8 weeks old male and female Wistar rats. This part of toxicity assessment provides preliminary tolerability and safety data to evaluate the acute action of a vaccine. The local tolerance and systemic toxicity of a single intramuscular dose (1 FHD in each 3 and 5 µg formulation and a threefold of 5 µg FHD) of vaccine was assessed in rat (Table 1 ). In-life assessment (clinical signs, local reactions and body weight), clinical pathology and histopathology of tissues (brain, liver, kidney, spleen, heart, gonad, site of administration and inguinal lymph node) were evaluated for any adverse alterations. [28] [29] [30] Repeated dose toxicity study

The primary goal of repeated dose toxicity studies is to characterise the adverse toxicological effects occurring because of repeated boosting with, or exposure, to a vaccine candidate for a specified period up to the expected lifespan of the test species. Male and female Wistar rats (n = 20) were injected 1FHD four times with 2 weeks intervals and 10 New Zealand white rabbits in both sexes administrated by 1FHD vaccine three times (days 0, 14 and 28). Inlife assessment in addition to clinical pathology and histopathology were performed for both rats and rabbits. [27] [28] [29] [30] 

The pyrogen test in rabbits is based on the measurement of the increase in the rabbit's temperature upon being injected with a product that could contain a contaminant of the pyrogen type. To conduct the pyrogenicity assay, three adult rabbits for three consecutive batches of candidate vaccines were injected. One FHD vaccine substance was injected into the marginal vein of the rabbit's ear. The post-injection body temperature of rabbits was measured in the first, second and third hours using a special thermometer. 27 

Two doses of the inactivated purified virus (3 and 5 μg) as antigen alone or in combination with alum adjuvant were administrated to different animals to evaluate vaccine immunogenicity. The control group was injected with physiological saline (PBS).

Ten female BALB/c mice (6-8 weeks) were injected intramuscularly with 100 μL of different doses of the vaccine according to Table 2 on days 0 and 14. About 2, 4 and 5 weeks after the final immunisation, blood samples were collected by puncture of the retro-orbital vein.

The serum samples were taken to evaluate anti-whole virus particle, anti-spike glycoprotein (S), anti-receptor binding domain (RBD) IgG EDITORIAL and antibody isotyping profile (IgG1/IgG2a) by Enzyme-Linked Immunosorbent Assay (ELISA) and also conventional virusneutralising test (cVNT) was applied to analyse the vaccine's immunogenicity.

Ten BALB/c mice were injected with the candidate vaccine using the same protocol presented in Table 2 . Two weeks after the final immunisation, serum samples were collected to evaluate the vaccine's immunogenicity by virus-neutralising assay. Then, the animals were sacrificed, spleens were isolated and splenocyte culture supernatants were used for evaluating cellular immunity responses by Granzyme B (Gzm B) activity assay.

Fifty New Zealand White rabbits (3-6 months) were divided into two groups: the test and control groups. The test group was injected intramuscularly with 5 μg antigen in combination with alum adjuvant and the control group was injected with PBS. Immunisations were carried out three times (on days 0, 14 and 28) using 5 μg of antigens in Horseradish peroxidase-conjugated goat anti-mouse IgG antibody (RaziBiotec AP8036) at 1/5000 dilution was added to the wells and after washing with PBST, the plates were incubated for 1.5 h at 37°C.

Colourimetric detection was performed using 100 µL 3,3 0 ,5,5 0 -Tetramethylbenzidine (TMB, Sigma) as substrate after washing and incubation for 30 min at RT. The reaction was stopped with 50 μL H 2 SO 4 (2 N), and absorbance was measured at 450 nm using an ELISA reader.

Furthermore, in serum samples of the mice, rabbits and monkey groups, S-specific and RBD-specific IgG antibody titres were deter- 

Data were analysed by GraphPad Prism 7 software, using one-way ANOVA and two-way ANOVA followed by Tukey's post hoc test. A P-value of P ≤ 0.01 was considered statistically significant.

The SARS-CoV-2 used in developing the BIV1-CovIran vaccine was retrieved from a nasopharyngeal sample from a COVID-19 patient.

The sample propagation and virus isolation were performed in the (Figures S2 and 4) . It was found that the formulated vaccine (antigen + alum) increased the antibody titre after F I G U R E 4 Induction of specific IgG antibodies by different vaccine preparation in mice groups. Immunisations were carried out two times during 2 weeks with 100 μL intramuscular injection of different vaccine preparations according to Table 1 . A PBS solution containing three or 5 μg of purified inactivated viruses as antigens, administered alone or in combination with alum. The control groups received alum or PBS. Anti-whole virus particle IgG, Anti-spike glycoprotein (S) IgG and Anti-receptor binding domain (RBD) IgG antibody titres in different dilutions of serum were assayed by ELISA at 2, 4 and 5 weeks post-immunisation. Data are mean � SD. The levels of statistical significance for differences between test groups were determined using two-way ANOVA followed by Tukey's post hoc test. a: Statistical significance (P < 0.0001) in comparison with groups that received 3 or 5 μg antigen alone and b: Statistical significance (P < 0.0001) between groups that received 3 μg antigens + alum and groups immunised with 5 μg antigens + alum 42 days due to antigen storage, while antibody titres decreased in the group that received only antigen in the same period. The production of specific antibodies against S and RBD showed a significant increase in the groups receiving 3 and 5 μg of antigen + alum compared to the other groups. Antibody titres also increase over a period of 2-5 weeks. In the second week, the antibody titre in the group receiving 5 μg of antigen + alum was significantly higher than the antibody titre in the group receiving 3 μg of antigen + alum, but the antibody titre in the fourth and fifth weeks in both groups was equal (Figures 4 and S1 ). In addition, IgG1 and IgG2a antibodies were raised in all mice that received the alum formulated ( Figure 5 )

Rabbits In order to determine the repeated dose toxicity and the amount of antibody production, vaccination of the rabbits was repeated 3 times (on days 0, 14 and 28). On the 28th days after the last injection, the animals were bled, and serum samples (at dilution 1/20,000) were taken for antibody evaluation by indirect ELISA. As illustrated in Figure 6 , the titre of S and RBD-specific IgG was significantly (P < 0.05) higher than the control group. 

A number of biochemical and haematological indicators were measured at different time points post-immunisation. There was no significant difference in terms of biochemical markers in the vaccinated animals ( Figure S2 ). Haematological analysis after viral challenge in 3 μg vaccinated and control animals showed lymphocytosis ( Figure S3 ).

A number of key cytokines in the spleen cell culture supernatant of mice groups were measured 2 weeks after last immunisation by ELISA kits. The results showed that the IFN-γ and TNF-α secretion levels significantly increased in groups receiving antigen + alum compared to the groups receiving antigen alone. The highest level of IL-4 was produced in the group receiving 5 μg of antigen + alum, which shows a significant increase compared to other groups. A significant level of IL-17 in the groups receiving antigen + alum was induced, while very low levels of IL-17 were seen in the other groups ( Figure 9 ). Besides, several cytokines in serum samples of monkeys were measured over times after immunisation by ELISA kits. The results showed that IFN-γ, TNFα and IL-6 (inflammatory cytokines) in vaccinated macaques have been F I G U R E 7 Induction of specific IgG antibodies by candidate vaccine in monkey groups. Rhesus macaques were intramuscularly immunised two times (at days 0 and 14) with 3 or 5 μg doses of candidate vaccine (antigen + alum). The control group was injected with PBS. The challenge study was carried out 14 days after the second immunisation. Anti-spike glycoprotein (S) and anti-receptor binding domain (RBD) IgG antibody titre in serum samples of monkey groups was determined by ELISA over time and data are reported as mean � SD. The statistically significant differences between groups were determined using two-way ANOVA followed by Tukey's post hoc test. (b) Statistical significance (P < 0.01) between vaccinated groups F I G U R E 8 Conventional virus neutralisation test (cVNT) in animal groups that received different vaccine preparations EDITORIAL increased in serum after vaccination. But after challenge, TNF-α and IL-6 decreased in vaccinated groups, while these main inflammatory cytokines rise in control group. TNF-α and IL-6 decreased in vaccinated groups, while these main inflammatory cytokines rise in control group after challenge. Although vaccination has somewhat increased IL-4 in both vaccinated groups, it has increased in all groups after the challenge ( Figure 10 ).

The lung tissue samples were used for protein extraction. The total protein concentration was determined by the Bradford assay. The Figure 11 ).

The potential for induction of cellular immunity at different vaccine concentrations was evaluated by measurement of Gzm B activity using ELISA. The results revealed that Gzm B activity increased in the mice immunised with a mixture of antigen and alum adjuvant in comparison with the animals that received only antigen (P < 0.0001).

Furthermore, there was a significant increase in Gzm B activity in the group that received the 5 μg dose of antigen + alum in comparison to the group which was immunised with the 3 μg dose of antigen + alum ( Figure 12 ).

Rhesus macaques injected with 3 μg candidate vaccine showed a significant reduction in lung virus titre titres compared with PBS-F I G U R E 9 Measurement of cytokine levels secreted by splenocytes of immunised mice. BALB/c mice were immunised two times biweekly, and 2-week post-immunisation, spleens were harvested. Splenocytes were isolated and stimulated ex vivo in the presence of the purified inactivated virus 60 h. Cytokines released into culture media were determined by ELISA kit. Data are mean � SD. The levels of statistical significance for differences between test groups were determined using ANOVA followed by Tukey's post hoc test. *Statistical significance (P < 0.05) treated controls. The titre of virus was 10 2 TCID50/mL in the group that received 3 μg while the PBS injected group had 10 6 TCID50/mL.

A higher level of viral clearance was detected in rhesus macaques immunised with 5 μg candidate vaccine and no viruses were detected ( Figure 13 ).

The immune cell subsets in the peripheral blood were assessed in SARS-CoV-2 challenged macaques using flow cytometry method after challenge. Lymphocytes population in flow cytometric evaluation of post-challenged animals showed that the total percentage of lymphocytes significantly increased in the group receiving 3 μg antigen + alum (% 52.6), compared to the group receiving 5 μg antigen + alum (% 27.9) and the control group (29.7%) which is associated with a shift to cellular immunity and the production of cytotoxic CD8 + lymphocytes ( Figure 14 ). In the group receiving 5 μg antigen + alum, although the overall percentage of lymphocytes did not change significantly compared to the control group, the lymphocyte shifts as in the group receiving 3 μg antigen + alum is towards the production of cytotoxic CD8 + lymphocytes. As a consequence, lymphocyte subsets shifted from CD4 + to CD8 + (CD4 + :

29% and 22%, CD8 + : 56% and 58%) in the vaccinated groups. Also, from the ratio of CD8 + to CD4 + lymphocytes (1. 

Histopathological evaluation of various organs, heart, spleen, liver, kidney and brain in the vaccinated monkeys revealed no obvious lesion in the vaccinated animals. In infected control animals, in addition to severe lung lesions, renal tubular epithelium necrosis was found, probably due to SARS-CoV-2. Histopathology of lung in infected control animals showed progressive moderate-to-severe interstitial pneumonia accompanied by macrophage and lymphocyte infiltration, particularly in the cranial and middle lobes. Moreover, we found F I G U R E 1 0 Cytokine level in serum samples of monkeys. Macaques were immunised two times on days 0 and 14 through the intramuscular route with 3 or 5 μg antigen + alum. The control group was injected with PBS. A number of key cytokines in serum samples were measured over times after immunisation by ELISA kits. Data presented as mean � SD. The statistically significant differences between groups were determined using two-way ANOVA followed by Tukey's post hoc test moderate-to-severe thickening of alveolar septa with type II pneumocyte hyperplasia and fibrin deposition. Vasculitis with accumulation of lymphocytes around small vessels was detected in control monkeys' lung tissue sections. In the vaccinated animals, the lung tissue showed diffuse mild interstitial pneumonia and mild bronchial epithelial necrosis limited to some areas in the cranial lobes ( Figure 15 ). Immunohistochemically characterisation of immune cell population within the lung tissue sections revealed that the highest presence of CD68 positive M1 macrophages was detected in infected control monkeys. CD4 F I G U R E 1 1 Cytokine level in homogenised lung tissue samples. Macaques were immunised two times on days 0 and 14 through the intramuscular route with 3 or 5 μg antigen + alum. The control group was injected with PBS. A number of key cytokines in lung tissues were measured on day 45 after immunisation by western blot analysis. The lung tissue samples were used for protein extraction. The total protein concentration was determined by the Bradford assay. Assessment of IL-6, IL-4, IL-10 and IFN-γ in lung extracted proteins was performed by SDS-PAGE followed by western blot analysis. Data presented as mean � SD. The statistically significant differences between groups were determined using two-way ANOVA followed by Tukey's post hoc test. Asterisks indicate significance: *P < 0.05, **P < 0.001, ***P < 0.0001 and ****P < 0.00001 in comparison with the control group F I G U R E 1 2 Measurement of Gzm B activity in mice groups that received different vaccine preparations. Immunisations were carried out two times over 2 weeks with 100 μL intramuscular injection of different vaccine preparations. The control groups received alum or PBS. At 2 weeks after the last immunisation, spleens were isolated from immunised mice and Gzm B activity was measured. Data are reported as mean � SD. The levels of statistical significance for differences between test groups were determined using one-way ANOVA followed by Tukey's post hoc test. 

Scientists have focused their efforts on the development of vaccines to stop the COVID-19 pandemic and its quick spread. 38 To achieve this goal, several vaccine trials are being conducted worldwide. For decades, inactivated whole particle vaccines have been broadly administrated to prevent emerging respiratory diseases. 39 The results from preclinical and clinical studies of three inactivated COVID-19 vaccines have shown promising outcomes against SARS-CoV-2. [40] [41] [42] On the other hand, the application of adjuvants in vaccine formulation can increase and/or modulate the intrinsic immunogenicity of antigen and elicit strong and long-lasting immune responses. 43 It may also substantially reduce the amount of antigen and/or the number of boost injections required to achieve the desired immune responses. 44 Meanwhile, alum adjuvant works primarily through the formation of a depot at the injection site, enabling Levels of IL-10, an anti-inflammatory cytokine, increased at the end of immune response. As with TGF-β, the immune system shifts F I G U R E 1 6 Immunohistochemical staining of immune cells within the lung tissue sections back to low function which is necessary for prevention of severe immune system response and incidence of over activation of immune system diseases. In contrast, virus-induced inflammation may trigger the immune system but, with low amount of IL-10, does not terminate immune system activity. Consequently, this endless immune system activity leads to pathologic effect of SARS-COV-2 virus.

The IFN-γ cytokine, known as an amplifier and stimulator cyto- One concern about COVID-19 vaccines is the antibodydependent enhancement (ADE) phenomenon, whereby the vaccine might make the subsequent SARS-CoV-2 infection more severe. 39, 48 The ADE phenomenon has been reported in studies of Middle East respiratory syndrome-CoV and SARS-CoV-2 vaccines in animal challenge models. 49 However, this effect was not observed in an immunisation-challenge model of Rhesus macaques using the same vaccines in the preclinical study or in the reports from preclinical studies of other inactivated COVID-19 vaccine candidates. 40, 50 Studies have shown that previous infection with SARS-CoV-2 could protect against re-challenge in Rhesus macaques. The ADE phenomenon may happen due to an imbalance between Th1 and Th2 responses. 51, 52 Another concern associated with whole-inactivated virus-based vaccines, particularly those with the alum adjuvant that can induce 

History of vaccination

Immunological considerations for COVID-19 vaccine strategies

Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: a randomized, single-blind, placebo-controlled phase 1 clinical trial with a 6 months follow-up and an open-label phase 2 clinical trial in Kazakhstan

Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome

Vaccine Analysis: Strategies, Principles, and Control

Vaccination of human subjects with virus of human influenza

Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines

An inactivated hepatitis A viral vaccine of cell culture origin

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Antibody responses to SARS-CoV-2 in patients with COVID-19

Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2

Protection from mouse hepatitis virus type 3-induced acute disease by an antinucleoprotein monoclonal antibody

Duration of antibody responses after severe acute respiratory syndrome

Towards an understanding of the adjuvant action of aluminium

Covid-19: time for a paradigm change

Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections

COVID-19 vaccine design: the Janus face of immune enhancement

COVID-19): Interim Guidance. World Health Organization

Determining influenza virus shedding at different time points in Madin-Darby canine kidney cell line

On the analysis of psychometric functions: the Spearman-Kärber method

Recommendations for the Production and Control of Poliomyelitis Vaccine (Oral), World Health Organization

An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice

Reconstruction of H3N2 influenza virus based virosome in-vitro

Purification of human and avian influenza viruses using cellulose sulfate ester (cellufine sulfate) in the process of vaccine production

Cellufine sulfate column chromatography as a simple, rapid, and effective method to purify dengue virus

Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice

The British Pharmacopoeia

The Stationery Office

Study designs for the nonclinical safety testing of new vaccine products

A Comprehensive Guide to Toxicology in Nonclinical Drug Development

Scientific and Regulatory Policy Committee points to consider*: approaches to the conduct and interpretation of vaccine safety studies for clinical and anatomic pathologists

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Establishment of an African Green Monkey Model for COVID-19

Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)

Differences in antibody kinetics and functionality between severe and mild severe acute respiratory syndrome coronavirus 2 infections

Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach

Integrative analyses of SARS-CoV-2 genomes from different geographical locations reveal unique features potentially consequential to host-virus interaction, pathogenesis and clues for novel therapies

Ter Meulen V. Lymphocyte subsets and expression of differentiation markers in blood and lymphoid organs of rhesus monkeys

Race for COVID-19 vaccine

Key steps in vaccine development

Development of an inactivated vaccine candidate for SARS-CoV-2

Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials

Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine

The ABC of clinical and experimental adjuvants-a brief overview

Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine

Rapid COVID-19 vaccine development

Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

COVID19: Cross-Immunity with Other Coronaviruses, Immunopathological Phenomena. SSRN

Vaccination against SARS-CoV-2 and disease enhancement-knowns and unknowns

Altered Reactivity to Measles Virus

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement

We appreciate all the kind assistance of Dr. Mehrdad Jalilian to give us feedback to improve this manuscript and the site research staffs.This work is supported financially by Amirabad Virology Lab. Email: Hjalili@ut.ac.ir

The data that supports the findings of this study are available in the manuscript and supplementary material of this article.

https://orcid.org/0000-0002-1605-4471